Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 26.68
+0.18 (0.68%)
Jun 18, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 9.31 billion as of June 17, 2026. Its market cap has decreased by -32.11% in one year.
Market Cap
9.31B
Enterprise Value
7.31B
Revenue
1.90B
Ranking
n/a
PE Ratio
n/a
Stock Price
26.68
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 9.31B, a decrease of -54.87%. That is a compound annual growth rate of -13.04%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 18, 2026 | 9.31B | -28.71% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascentage Pharma Group International | 12.60B |
| Nanjing Leads Biolabs | 10.96B |
| GenFleet Therapeutics (Shanghai) | 10.63B |
| LongBio Pharma (Suzhou) | 10.59B |
| Ascletis Pharma | 9.93B |
| CARsgen Therapeutics Holdings | 9.42B |
| HBM Holdings | 9.18B |
| Suzhou Ribo Life Science | 8.56B |